Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 83

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
3 340
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 340 trials in Villejuif

Open in trial search

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Rectal cancer

Recruiting

Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Institut Regional Du Cancer De Montpellier

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Factor VIII deficiency

Recruiting

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Joint stabilisation

Recruiting

Study Comparing Rivaroxaban and Drug Combination for Preventing Blood Clots in Patients with Lower Limb Injuries Requiring Immobilization

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Breast cancer

Recruiting

Study on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Lymphoma+6

Recruiting

Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Novartis Pharma AG

Neoplasm

Recruiting

Study of AZD3470 alone and in combination with other cancer drugs for patients with advanced solid tumors that are MTAP deficient

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD3470
  • Sponsor:AstraZeneca AB

Osteochondrodysplasia

Recruiting

Study on the Safety and Effectiveness of TransCon CNP for Infants with Achondroplasia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Navepegritide
  • Sponsor:Ascendis Pharma Growth Disorders A/S

Haematological malignancy+1

Recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Aveo Pharmaceuticals Inc.

Cardiac amyloidosis+1

Recruiting

Long-Term Safety Study of NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy or Transthyretin Amyloidosis-Related Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Intellia Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.